Breakthrough in cancer immunotherapy: Dresden researchers present promising therapy for advanced solid tumors
Peer-Reviewed Publication
Updates every hour. Last Updated: 3-Jun-2026 18:17 ET (3-Jun-2026 22:17 GMT/UTC)
A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) in Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD Dresden University of Technology will present clinical results for the first time on May 31, 2026, at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) regarding a new cancer immunotherapy for the treatment of advanced tumors. The results show overall good tolerability and clear signs of effectiveness of this novel immunotherapy. They are published in the renowned scientific journal Nature Medicine.
Zinc oxide nanoparticles are widely incorporated into sunscreens, cosmetics, and topical formulations, yet their biological effects may change under microbe-rich skin conditions. This study shows that co-exposure to ZnO nanoparticles and Staphylococcus aureus markedly aggravates injury in HaCaT keratinocytes. ZnO-induced reactive oxygen species disrupt barrier integrity, impair mitochondrial function, activate apoptotic signaling, and promote inflammatory responses. The presence of S. aureus further amplifies these effects, partly through MAPK pathway activation. These findings highlight the need to evaluate nanomaterial safety in realistic skin microenvironment settings, especially for inflamed or barrier-impaired skin and products intended for daily use.
A humanitarian medical delegation of senior physicians and medical students has begun operating in Kenya as part of the “Humanitarian Elective,” an initiative focused on supporting local healthcare teams while providing participants with immersive clinical experience in resource-limited settings. Through hands-on work in emergency and pediatric medicine, students are learning to navigate medical crises, healthcare inequality, cultural differences, and severe shortages of equipment and infrastructure. Organizers hope the program will help shape a new generation of globally minded physicians and establish humanitarian medicine as a natural part of medical training.
Different types of liver disease are leading to distinct signatures of muscle loss, according to a new study which could help pave the way for more personalised treatments for sarcopenia in people with end‑stage liver disease.
The research was led by scientists at the University of Birmingham, published in the Journal of Cachexia, Sarcopenia and Muscle and delivered through the National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC): Birmingham. The study reveals for the first time that the underlying cause of liver disease shapes how muscle loss develops and how it may respond to treatment.